Literature DB >> 35074013

Dimensions of poverty as risk factors for antimicrobial resistant organisms in Canada: a structured narrative review.

Teagan King1, Richelle Schindler2,3, Swati Chavda4, John Conly4,5,6,7,8.   

Abstract

BACKGROUND: Few studies have assessed the relationship between poverty and the risk of infection with antimicrobial resistant organisms (AROs). We sought to identify, appraise, and synthesize the available published Canadian literature that analyzes living in poverty and risk of AROs.
METHODS: A structured narrative review methodology was used, including a systematic search of three databases: MedLINE, EMBASE and Web of Science for articles pertaining to poverty, and infection with AROs in Canada between 1990 and 2020. Poverty was broadly defined to include economic measures and associated social determinants of health. Based on inclusion and exclusion criteria, there were 889 initial articles, and 43 included in the final review. The final articles were extracted using a standard format and appraised using the Joanna Briggs Institute Levels of Evidence framework.
RESULTS: Of 43 studies, 15 (35%) related to methicillin-resistant Staphylococcus aureus (MRSA). One study found a 73% risk reduction (RR 0.27, 95%CI 0.19-0.39, p =  < 0.0001) in community-acquired MRSA (CA-MRSA) infection for each $100,000 income increase. Results pertaining to homelessness and MRSA suggested transmission was related to patterns of frequent drug use, skin-to-skin contact and sexual contact more than shelter contact. Indigenous persons have high rates of CA-MRSA, with more rooms in the house being a significant protective factor (OR 0.86, p = 0.023). One study found household income over $60,000 (OR 0.83, p = 0.039) in univariate analysis and higher maternal education (OR 0.76, 95%CI 0.63-0.92, p = 0.005) in multivariate analysis were protective for otitis media due to an ARO among children. Twenty of 43 (46.5%) articles pertained to tuberculosis (TB). Foreign-born persons were four times more likely to have resistant TB compared to Canadian-born persons. None of the 20 studies used income in their analyses.
CONCLUSIONS: There is an association between higher income and protection from CA-MRSA. Mixed results exist regarding the impact of homelessness and MRSA, demonstrating a nuanced relationship with behavioural risk factors. Higher income and maternal education were associated with reduced ARO-associated acute otitis media in children in one study. We do not have a robust understanding of the social measures of marginalization related to being foreign-born that contribute to higher rates of resistant TB infection.
© 2022. The Author(s).

Entities:  

Keywords:  Antimicrobial resistant organisms; Canada; Income; Narrative review; Poverty; Risk factors

Mesh:

Year:  2022        PMID: 35074013      PMCID: PMC8785485          DOI: 10.1186/s13756-022-01059-1

Source DB:  PubMed          Journal:  Antimicrob Resist Infect Control        ISSN: 2047-2994            Impact factor:   4.887


  52 in total

1.  Multidrug-resistant tuberculosis: long term follow-up of 40 non-HIV-infected patients.

Authors:  M Avendaño; R S Goldstein
Journal:  Can Respir J       Date:  2000 Sep-Oct       Impact factor: 2.409

2.  Continuing surveillance of invasive Haemophilus influenzae disease in northwestern Ontario emphasizes the importance of serotype a and non-typeable strains as causes of serious disease: a Canadian Immunization Research Network (CIRN) Study.

Authors:  Ashley Cerqueira; Sarah Byce; Raymond S W Tsang; Frances B Jamieson; Julianne V Kus; Marina Ulanova
Journal:  Can J Microbiol       Date:  2019-06-26       Impact factor: 2.419

3.  Determinants of carriage of resistant Staphylococcus aureus among S. aureus carriers in the Indonesian population inside and outside hospitals.

Authors:  Endang Sri Lestari; D Offra Duerink; Usman Hadi; Juliëtte A Severin; Nico J D Nagelkerke; Kuntaman Kuntaman; Hendro Wahjono; Widjoseno Gardjito; Ariawan Soejoenoes; Peterhans J Van Den Broek; Monique Keuter; Inge C Gyssens; Henri A Verbrugh
Journal:  Trop Med Int Health       Date:  2010-10       Impact factor: 2.622

4.  Methicillin-resistant Staphylococcus aureus in tertiary care institutions on the Canadian prairies 1990-1992.

Authors:  J Embil; K Ramotar; L Romance; M Alfa; J Conly; S Cronk; G Taylor; B Sutherland; T Louie; E Henderson
Journal:  Infect Control Hosp Epidemiol       Date:  1994-10       Impact factor: 3.254

5.  Tuberculosis drug resistance in Canada: 2017.

Authors:  M LaFreniere; H Hussain; J Vachon
Journal:  Can Commun Dis Rep       Date:  2018-11-01

6.  Active tuberculosis among homeless persons, Toronto, Ontario, Canada, 1998-2007.

Authors:  Kamran Khan; Elizabeth Rea; Cameron McDermaid; Rebecca Stuart; Catharine Chambers; Jun Wang; Angie Chan; Michael Gardam; Frances Jamieson; Jae Yang; Stephen W Hwang
Journal:  Emerg Infect Dis       Date:  2011-03       Impact factor: 6.883

7.  Out-of-pocket health expenditures and antimicrobial resistance in low-income and middle-income countries: an economic analysis.

Authors:  Marcella Alsan; Lena Schoemaker; Karen Eggleston; Nagamani Kammili; Prasanthi Kolli; Jay Bhattacharya
Journal:  Lancet Infect Dis       Date:  2015-07-09       Impact factor: 25.071

8.  SANRA-a scale for the quality assessment of narrative review articles.

Authors:  Christopher Baethge; Sandra Goldbeck-Wood; Stephan Mertens
Journal:  Res Integr Peer Rev       Date:  2019-03-26

9.  Sociodemographic and geospatial associations with community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections in a large Canadian city: an 11 year retrospective study.

Authors:  Victoria C Gill; Irene Ma; Maggie Guo; Dan B Gregson; Christopher Naugler; Deirdre L Church
Journal:  BMC Public Health       Date:  2019-07-09       Impact factor: 3.295

10.  Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics.

Authors:  Jessica Minion; Victor Gallant; Joyce Wolfe; Frances Jamieson; Richard Long
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.